Beyond "One Bug, One Drug" - Tonix Pharmaceuticals Secures Up To $34 Million In Funding From The U.S. Department Of Defense To Develop a Broad-Spectrum Antiviral
Tonix Pharmaceuticals (NASDAQ:TNXP) has secured up to $34 million in funding from the U.S. Department of Defense to develop broad-spectrum antiviral agents. The five-year deal with the Defense Threat Reduction Agency (DTRA) aims to improve the medical readiness of military personnel in biological threat environments. Tonix's program will focus on optimizing TNX-4200, an oral CD45 antagonist designed for broad-spectrum efficacy against various viral pathogens.
The company plans to leverage its research facilities, including a BSL-3 lab and ABSL-3 facility in Maryland, to accelerate development. This funding validates Tonix's ongoing research and in-house capabilities, supporting the advancement of its antiviral discovery program beyond the traditional 'one bug, one drug' approach.
Tonix Pharmaceuticals (NASDAQ:TNXP) ha ottenuto fino a 34 milioni di dollari di finanziamenti dal Dipartimento della Difesa degli Stati Uniti per sviluppare agenti antivirali a ampio spettro. L'accordo quinquennale con l'Agenzia per la Riduzione delle Minacce della Difesa (DTRA) ha l'obiettivo di migliorare la prontezza medica del personale militare in ambienti di minaccia biologica. Il programma di Tonix si concentrerà sull'ottimizzazione del TNX-4200, un antagonista CD45 orale progettato per un'azione efficace contro vari patogeni virali.
L'azienda prevede di sfruttare le sue strutture di ricerca, inclusi un laboratorio BSL-3 e una struttura ABSL-3 nel Maryland, per accelerare lo sviluppo. Questo finanziamento convalida la ricerca in corso di Tonix e le sue capacità interne, sostenendo il progresso del suo programma di scoperta antivirale oltre l'approccio tradizionale 'un microrganismo, un farmaco'.
Tonix Pharmaceuticals (NASDAQ:TNXP) ha obtenido hasta 34 millones de dólares en fondos del Departamento de Defensa de EE. UU. para desarrollar agentes antivirales de amplio espectro. El acuerdo de cinco años con la Agencia de Reducción de Amenazas de Defensa (DTRA) busca mejorar la preparación médica del personal militar en entornos de amenaza biológica. El programa de Tonix se centrará en optimizar TNX-4200, un antagonista oral de CD45 diseñado para eficacia de amplio espectro contra varios patógenos virales.
La compañía planea aprovechar sus instalaciones de investigación, que incluyen un laboratorio BSL-3 y una instalación ABSL-3 en Maryland, para acelerar el desarrollo. Este financiamiento valida la investigación continua de Tonix y sus capacidades internas, apoyando el avance de su programa de descubrimiento antiviral más allá del enfoque tradicional de 'un patógeno, un medicamento'.
Tonix Pharmaceuticals (NASDAQ:TNXP)는 U.S. 국방부로부터 최대 3천400만 달러의 자금을 확보하여 광범위한 항바이러스제를 개발하고 있습니다. 국방위협경감청(DTRA)과의 5년 계약은 생물학적 위협 환경에서 군인의 의료 준비태세를 개선하는 것을 목표로 하고 있습니다. Tonix의 프로그램은 다양한 바이러스 병원체에 대한 광범위한 효능을 위한 경구 CD45 길항제인 TNX-4200 최적화에 집중할 예정입니다.
회사는 메릴랜드에 있는 BSL-3 실험실과 ABSL-3 시설을 포함한 연구 시설을 활용하여 개발을 가속화할 계획입니다. 이번 자금 지원은 Tonix의 지속적인 연구와 내부 역량을 검증하며, 전통적인 '하나의 병원균, 하나의 약' 접근 방식을 넘어 항바이러스 발견 프로그램의 발전을 지원합니다.
Tonix Pharmaceuticals (NASDAQ:TNXP) a obtenu jusqu'à 34 millions de dollars de financement du Département de la Défense des États-Unis pour développer des agents antiviraux à large spectre. L'accord de cinq ans avec l'Agence de réduction des menaces de défense (DTRA) vise à améliorer la préparation médicale du personnel militaire dans des environnements de menaces biologiques. Le programme de Tonix se concentrera sur l'optimisation de TNX-4200, un antagoniste CD45 oral conçu pour une efficacité à large spectre contre divers agents pathogènes viraux.
L'entreprise prévoit d'exploiter ses installations de recherche, y compris un laboratoire BSL-3 et une installation ABSL-3 dans le Maryland, pour accélérer le développement. Ce financement valide la recherche en cours de Tonix et ses capacités internes, soutenant l'avancement de son programme de découverte antivirale au-delà de l'approche traditionnelle 'un microbe, un médicament'.
Die Tonix Pharmaceuticals (NASDAQ:TNXP) hat bis zu 34 Millionen Dollar an Finanzierung vom US-Verteidigungsministerium erhalten, um breit wirksame antivirale Mittel zu entwickeln. Der fünfjährige Vertrag mit der Defense Threat Reduction Agency (DTRA) zielt darauf ab, die medizinische Einsatzbereitschaft des Militärs in biologischen Bedrohungsumgebungen zu verbessern. Das Programm von Tonix wird sich auf die Optimierung von TNX-4200 konzentrieren, einem oralen CD45-Antagonisten, der für breit gefächerte Wirksamkeit gegen verschiedene Viruspathogene entwickelt wurde.
Das Unternehmen plant, seine Forschungseinrichtungen, einschließlich eines BSL-3-Labors und einer ABSL-3-Anlage in Maryland, zu nutzen, um die Entwicklung zu beschleunigen. Diese Finanzierung bestätigt die fortlaufende Forschung und die internen Fähigkeiten von Tonix und unterstützt den Fortschritt seines Antiviral-Entwicklungsprogramms über den traditionellen Ansatz 'ein Keim, ein Medikament' hinaus.
- Secured up to $34 million in funding from the U.S. Department of Defense
- Five-year contract to develop broad-spectrum antiviral agents
- Potential to address multiple viral threats with a single drug
- Access to state-of-the-art research facilities to accelerate development
- Validation of ongoing research and in-house capabilities
- None.
The U.S. Department of Defense's allocation of up to
The development of TNX-4200, a broad-spectrum antiviral targeting the CD45 protein, represents a significant leap in antiviral therapy. Unlike traditional 'one bug, one drug' models, this approach aims to combat multiple viral threats with a single medication. This is particularly relevant as viral pathogens evolve and diversify. The CD45 proteins' inhibition could offer broad-spectrum efficacy, a important advantage in biothreat scenarios. If Tonix's research yields successful results in animal trials and human studies, it could revolutionize antiviral treatments and secure a dominant market position, benefiting long-term shareholders.
The antiviral market is projected to reach
CHATHAM, NJ / ACCESSWIRE / July 24, 2024 / From anthrax to the plague, biological warfare is a real threat to U.S. forces and civilians, so much so the Pentagon budgeted about
![](https://www.accesswire.com/imagelibrary/64179b2e-754e-4c62-9ecd-5db2f78cbfe4/891641/military.jpg?v=1)
That's the case with Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP), a fully integrated biopharmaceutical company. The DoD's Defense Threat Reduction Agency (DTRA) recently inked a five-year deal with Tonix Pharmaceuticals to develop small molecule broad-spectrum antiviral agents for the prevention or treatment of infections to improve the medical readiness of military personnel in biological threat environments. Through the Other Transaction Agreement (OTA) contracting vehicle, Tonix could get as much as
"Through our agreement with DTRA, our broad-spectrum antiviral research program will address the DoD's goal of protecting U.S. forces in the event biological weapons are introduced onto the battlefield," said Seth Lederman, M.D., President and Chief Executive Officer of Tonix. "This funding provides important validation for our ongoing research and current in-house capabilities and will enable Tonix to advance its antiviral discovery program."
Stop Viruses In Their Tracks
Antiviral drugs are designed to stop a virus in its tracks by either attacking it or preventing it from spreading. In the case of Tonix's program, the goal is to fortify the immune system so that it can protect against a range of viruses. Demand for antiviral drugs is rising along with the concerns about viruses on the battlefield. Viruses are changing, jumping back and forth between humans and animals and there's the new risk that synthetic biology can be used maliciously, to make new viruses or to make existing viruses more virulent in what's called "gain of function". On the battlefield, the DoD is looking for antiviral drugs that can protect soldiers regardless of the agent. It is pouring money into different initiatives designed to react in the event of a biological attack.
Take DTRA's Chemical and Biological Technologies Department which is sponsoring Tonix's research. The department, which is funded out of DTRA's approximately
Across the U.S. government, chemical and biological countermeasures programs have approximately
Attacking The CD45 Protein
Tonix Pharmaceuticals' program will focus on optimizing and developing TNX-4200, the company's oral CD45 antagonist program, which is designed to have broad-spectrum efficacy against a range of viral pathogens. This broad-spectrum capability is a move beyond the previous "one bug, one drug" approach and seeks to target a broad range of deadly agents through just a single drug. Reduction of CD45 activity, a protein tyrosine phosphatase, protects animals against many viruses, including the Ebola virus. Through this funding, Tonix expects to establish the treatment's biological activity and safety in animals and then submit an Investigational New Drug application (IND) to conduct a first-in-human phase 1 clinical study.
Tonix said it plans to leverage previous research on phosphatase inhibitors - specifically compounds that target CD45 - to optimize compounds for therapeutic intervention of biothreat agents and provide the government with a broad-spectrum medical countermeasure. The idea behind Tonix's compound is that partial inhibition of CD45 will provide optimal antiviral protection with an acceptable safety profile. The
Leveraging R&D Capabilities
To develop its program, Tonix plans to rely on what it says are state-of-the-art research laboratory capabilities, including a Biosafety Level 3 (BSL-3) lab and an Animal Biosafety Level 3 (ABSL-3) facility at its research and development center in Frederick, Maryland. The research center is located in Maryland's I-270 biotech corridor and is close to the center of the U.S. biodefense research community. The research facilities will help to accelerate the development of vaccines and antiviral drugs against infectious diseases.
The threat of viruses, pandemics and biochemical attacks is increasing, driving demand for antivirals that can stop pathogens in their tracks. Tonix is betting it can deliver a single remedy to cover several viruses - and has up to
Featured photo by api.army.mil.
Click here for more information on Tonix Pharmaceuticals: https://redingtonvirtual.com/tnxp-aw-24072/
Investor Contact
Jessica Morris
Tonix Pharmaceuticals
investor.relations@tonixpharma.com
(862) 904-8182
Important notice, please read: Certain statements in this document are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimate," "expect," and "intend," among others. These forward-looking statements are based on Tonix's current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, risks related to the failure to obtain FDA clearances or approvals and noncompliance with FDA regulations; risks related to the failure to successfully market any of our products; risks related to the timing and progress of clinical development of our product candidates; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payor reimbursement; limited research and development efforts and dependence upon third parties; and substantial competition As with any pharmaceutical under development, there are significant risks in the development, regulatory approval, and commercialization of new products. Tonix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (the "SEC") on April 1, 2024, and periodic reports filed with the SEC on or after the date thereof. All Tonix's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof. This is not a solicitation of any offer to buy or sell. Redington, Inc. is paid by Tonix Pharmaceuticals Holding Corp. for investor relations services, and its employees or members of their families may from time to time own an equity interest in companies mentioned herein.
SOURCE: Tonix Pharmaceuticals Holding Corp.
View the original press release on accesswire.com
FAQ
What is the value of the contract Tonix Pharmaceuticals (TNXP) secured from the U.S. Department of Defense?
What is the main focus of Tonix Pharmaceuticals' (TNXP) antiviral research program?
How does Tonix Pharmaceuticals' (TNXP) approach differ from traditional antiviral development?